8/2/2006 5:03:18 PM
Makoto Life Sciences, Inc. announced today that it has signed a Funded Research Agreement with Taiho Pharmaceutical Co., Ltd of Japan. Under the terms of the Agreement, which provides research funding, potential future milestone and royalty payments, the companies will collaborate and leverage Makoto’s multi-component platform for applications in small molecule target identification. Target identification is among the most challenging problems along the critical path to drug discovery and development. Makoto’s integrated approach will be utilized under the Agreement to identify targets within disease pathways in several therapeutic areas, including, oncology, urology and allergic inflammation, and will facilitate further drug development activities at Taiho.
comments powered by